NRx Pharmaceuticals, Inc. (NRXPW)
- Previous Close
0.0610 - Open
0.0650 - Bid --
- Ask --
- Day's Range
0.0650 - 0.0650 - 52 Week Range
0.0650 - 0.0650 - Volume
198 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 1.45
- PE Ratio (TTM)
-- - EPS (TTM)
-6.2470 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
www.nrxpharma.comRecent News: NRXPW
View More
Compare To: NRXPW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NRXPW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-224.60%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-25.13M
Diluted EPS (ttm)
-6.2470
Balance Sheet and Cash Flow
Total Cash (mrq)
1.44M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
126.25k